Application of pharmacogenomics in clinical pharmacology

Toxicology Mechanisms and Methods

Volumn 16, Issue 2-3, 2006, Pages 89-99

  Huang, Shiew Mei ^a   Goodsaid, Federico ^a   Rahman, Atiqur ^a   Frueh, Felix ^a   Lesko, Lawrence J ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Clinical Pharmacology; Pharmacogenomics Application

Indexed keywords

ALOSETRON; ASTEMIZOLE; ATOMOXETINE; AZATHIOPRINE; BROMFENAC; CERIVASTATIN; CISAPRIDE; CODEINE; CYCLOSPORIN A; DEXFENFLURAMINE; DIGOXIN; DRUG METABOLIZING ENZYME; EFAVIRENZ; FENFLURAMINE; FEXOFENADINE; GREPAFLOXACIN; IRINOTECAN; MERCAPTOPURINE; METOPROLOL; MIBEFRADIL; NELFINAVIR; OMEPRAZOLE; PRAVASTATIN; RAPACURONIUM BROMIDE; REPAGLINIDE; ROFECOXIB; TERFENADINE; TROGLITAZONE; TSUKUBAENOLIDE; UNINDEXED DRUG; WARFARIN;

AREA UNDER THE CURVE; BLOOD DISEASE; BONE MARROW TOXICITY; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLINICAL PHARMACOLOGY; CONSTIPATION; DIABETES MELLITUS; DISEASE MARKER; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG INFORMATION; DRUG LABELING; DRUG MARKETING; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME ACTIVITY; FOOD AND DRUG ADMINISTRATION; GENETIC POLYMORPHISM; HEARTBURN; HETEROZYGOSITY; HOMOZYGOSITY; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IRRITABLE COLON; ISCHEMIC COLITIS; LIVER FAILURE; NEUTROPENIA; OBESITY; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK REDUCTION; STABLE ANGINA PECTORIS; STOMACH PH; TORSADE DES POINTES; VALVULAR HEART DISEASE;

EID: 33645010143     PISSN: 15376516     EISSN: 15376524     Source Type: Journal    
DOI: 10.1080/15376520600558333     Document Type: Review

References (96)

1. Andersson, T., Cederberg, C., Edvardsson, G., Heggelund, A., and Lundborg, P. 1990. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin. Pharmacol. Ther. 47:79-85.
2. Andersson, T., Flockhart, D. A., Goldstein, D. B., Huang, S.-M., Kroetz, D. L., Milos, P. M., Ratain, M. J., and Thummel, K. 2005. Drug Metabolizing Enzymes-Evidence for Clinical Utility of Pharmacogenomic Tests. Clin. Pharmacol. Ther. 78(6):559-581.
3. Andersson, T. "Special consideration of individual metabolic biomarkers: CYP2C19" presentation at the FDA/PhRMA/JHU educational workshop, September 13-14, 2004, Rockville, MD: http://www.fda.gov/cder/ offices/ocpb/workshops.htm [accessed June 2, 2005].
4. Blaisdell, J., Mohrenweiser, H., Jackson, J., Ferguson, S., Coulter, S., Chanas, B., Xi, T., Ghanayem, B., and Goldstein, J. A. 2002. Identification and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenetics 12:703-711.
5. Chasman, D. I., Posada, D., Subrahmanyan, L., Cook, N. R., Stanton, V. P. Jr, and Ridker, P. M. 2004. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 291:2821-2827.
6. Cross, J., Lee, H., Westelinck, A., Nelson, J., Grudzinskas, C., and Peck, C. 2002. Postmarketing drug dosage changes of 499 PDA-approved new molecular entities, 1980-1999. Pharmacoepidemiol Drug Saf. 11:439-446.
7. Dai, D., Tang, J., Rose, R., Hodgson, E., Bienstock, R.J., Mohrenweiser, H.W., and Goldstein, J.A. 2001. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J. Pharmacol. Exp. Ther. 299:825-831.
8. DIA/FDA workshop: Co-Development of Drug, Biological and Device Products, 29 July 2004, Arlington, VA. Washington, DC: U.S. Food and Drug Administration/Horsham, PA: Drug Information Association. Available: http://www.diahome.org/Content/Events/04040.pdf [accessed August 31 2004].
9. Eckhardt, K., Li, S., Ammon, S., Schanzle, G., Mikus, G., and Eichelbaum, M. 1998. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain 76:27-33.
10. Evans, W. E., and Relling, M. V. 1999. Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics. Science 286:487-491.
11. Evans, W. E., Hon, Y. Y., Bomgaars, L., Coutre, S., Holdsworth, M., Janco, R., Kalwinsky, D., Keller, F., Khatib, Z., Margolin, J., Murray, J., Quinn, J., Ravindranath, Y., Ritchey, K., Roberts, W., Rogers, Z. R., Schiff, D., Steuber, C., Tucci, F., Kornegay, N., Krynetski, E. Y., and Relling, M. 2001. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J. Clin. Oncol. 19:2293-2301.
12. Evans, W. E., and McLeod, H. L. 2003. Pharmacogenomics-drug disposition, drug targets, and side effects. N. Engl. J. Med. 348:538-549.
13. Evans, W. E., and Relling, M. V. 2004. Moving towards individualized medicine with pharmacogenomics. Nature 429:464-468.
14. Evans, W. E. 2004. Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Ther. Drug. Monit. 26:186-191.
15. FDA MAPP: Clinical Pharmacology and Biopharmaceutics NDA Review Template (Issued 4/27/2004, Posted 6/24/2004): http://www.fda.gov/cder/ mapp/4000.4.pdf (last accessed August 31, 2004).
16. Food and Drug Administration (FDA) strategic plan: FDA Commissioner, McClellan, MB, FDA Strategic Action Plan; August 2003: http://www. fda.gov/oc/mcclellan/strategic.html.
17. FDA Advisory Committee for Pharmaceutical Sciences; Clinical Pharmacology Subcommittee meeting 2005, http://www.fda.gov/ohrms/dockets/ac/ cder05.html#PharmScience; labeling recommendations: http://www.fda. gov/ohrms/dockets/ac/05/briefing/2005-4194B1 03 Topic-1A.pdf; http:// www.fda.gov/ohrms/dockets/ac/05/slides/2005-4194S1 Slide-Index.htm; http://www.fda.gov/ohrms/dockets/ac/05/slides/2005-4194S1 02 01-Huang. ppt
18. FDA CDER/CBER Guidance for Industry: Exposure-Response Relationships-Study Design, Data Analysis, and Regulatory Applications: http://www. fda.gov/cder/guidance/5341fn1.pdf, May 2003.
19. FDA Mission Statement. 2004: http://www.fda.gov/opacom/morechoices/ mmission.html [accessed September 4, 2004].
20. FDA whitepaper, 2004. Innovation or Stagnation, challenge and opportunity on the critical path to new medical products: http://www.fda.gov/oc/ initiatives/criticalpath/whitepaper.html [accessed September 4 2004].
21. FDA CDER/CBER/CDRH Guidance for industry: Pharmacogenomic data submission, posted on March 22, 2005: http://www.fda.gov/cder/ guidance/6400fnl.pdf [accessed March 25, 2005].
22. FDA CDER/CBER/CDRH Guidance for industry: Pharmacogenomic data submission, Examples of Voluntary Submissions or Submissions Required Under 21 CFR 312, 314, or 601, posted on March 22, 2005: http://www. fda.gov/cder/ guidance/6400fnlAttch.pdf [accessed March 25, 2005].
23. FDA Labeling information from: http://www.accessdata.fda.gov/scripts/ cder/ drugsatfda, http://www.fda.gov/cder/approval/index.htm or Physicians' Desk Reference at http://pdrel.thomsonhc.com/pdrel/librarian.
24. FDA Purinenthol labeling: http://www.fda.gov/cder/foi/label/2004/ 09053s0241bl. pdf [last accessed September 18, 2004].
25. FDA Atomoxetine clinical pharmacology review: http://www.fda.gov/ cder/foi/nda/2002/21-411-Strattera_biopharmr_P1.pdf 2002.
26. FDA, CDRH Guidance for Industry and FDA Staff, Class II Special Controls Guidance Document: Instrumentation for Clinical Multiplex Test Systems: http://www.fda.gov/cdrh/oivd/guidance/1546.html, March, 2005.
27. FDA CDRH Guidance for Industry and FDA Staff, Class II Special Controls Guidance Document: Drug Metabolizing Enzyme Genotyping System: http://www.fda.gov/cdrh/oivd/guidance/1551.html, March, 2005.
28. FDA Drug-diagnostic co-development concept paper, April 2005: http://www.fda.gov/cder/genomics/pharmacoconceptfn.pdf [accessed April 22, 2005].
29. FDA Draft guidance for industry Labeling for Human Prescription Drug and Biological Products - Implementing the New Content and Format Requirements http://www.fda.gov/cder/guidance/6005dft.pdf [accessed January 21, 2006]
30. FDA workshop: FDA/PhRMA/JHU educational workshop, September 13-14, 2004, Rockville, MD: http://www.fda.gov/cder/offices/ocpb/workshops.htm [accessed June 2, 2005].
31. FR notice 2000: Labeling guideline (Federal Register 65: 247; 81082-81131; December 22, 2000).
32. Fellay, J., Marzolini, C., Meaden, E. R., Back, D. J., Buclin, T., Chave, J. P., Decosterd, L. A., Furrer, H., Opravil, M., Pantaleo, G., Retelska, D., Ruiz, L., Schinkel, A. H., Vernazza, P., Eap, C. B., and Telenti, A. 2002. Swiss HIV Cohort Study, Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: A pharmacogenetics study. Lancet. 359:30-36.
33. Flockhart, D. "Special consideration of individual metabolic biomarkers: CYP2D6" presentation at the FDA/PhRMA/JHU educational workshop, September 13-14, 2004, Rockville, MD: http://www.fda.gov/cder/offices/ ocpb/workshops.htm [accessed June 2, 2005].
34. Frueh, F. W., Huang, S.-M., and Lesko, L. J. 2004. 112-12 editorial: Regulatory acceptance of toxicogenomics data. Environ. Health Perspect. 112:A663-A664.
35. Frueh, F. W., Goodsaid, F., Rudman, A., Huang, S.-M., and Lesko, L. J. 2005. The Need for Education in Pharmacogenomics: A regulatory perspective. Pharmacogenomics J. 5:218-220.
36. Furman, K. D., Grimm, D. R., Mueller, T., Holley-Shanks, R. R., Bertz, R. J., Williams, L. A., Spear, B. B., and Katz, D. A. 2004. Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics. Pharmacogenetics 14:279-284.
37. Furuta, T., Shirai, N., Sugimoto, M., Ohashi, K., Ishizaki, T. 2004. Pharmacogenomics of proton pump inhibitors. Pharmacogenomics 5:181-202.
38. Gaedigk, A., Bradford, L. D., Marcucci, K. A., Leeder, J. S. 2002. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin. Pharmacol. Ther. 72:76-89.
39. Goodsaid, F., Huang, S.-M., Frueh, F., Temple, R., and Lesko, L. J. Regulatory Guidance and Application of Genomic Biomarkers in Drug Development in "Principles of Clinical Pharmacogenomics," ed., Steven H. Y. Wong, Mark Linder, Roland Valdes, AACC Press (in press).
40. Hamelin, B. A., Bouayad, A., Methot, J., Jobin, J., Desgagnes, P., Poirier, P., Allaire, J., Dumesnil, J., and Turgeon, J. 2000. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. Clin. Pharmacol. Ther. 67:466-177.
41. Haufroid, V., Mourad, M., Van Kerckhove, V., Wawrzyniak, J., De Meyer, M., Eddour, D. C., Malaise, J., Lison, D., Squifflet, J. P., and Wallemacq, P. 2004. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14:147-154.
42. Hetherington, S., Hughes, A. R., Mosteller, M., Shortino, D., Baker, K. L., Spreen, W., Lai, E., Davies, K., Handley, A., Dow, D. J., Fling, M. E., Stocum, M., Bowman, C., Thurmond, L. M., and Roses, A. D. 2002. Genetic variations in HLA-B region andhypersensitivity reactions to abacavir. Lancet 359:1121-1122.
43. Higashi, M. K., Veenstra, D. L., Kondo, L. M., et al. 2002. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287:1690-1698.
44. HIll, M. A., Wilke, R. A., Caldwell, M. D., Berg, R. L., Glurich, I., and Burmester, J. K. 2004. Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. Pharmacogenetics 4:539-547.
45. Hoffmeyer, S., Burk, O., von Richter, O., Arnold, H. P., Brockmoller, J., Johne, A., Cascorbi, I., Gerloff, T., Roots, I., Eichelbaum, M., Brinkmann, U. 2000. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 97:3473-3478.
46. Huang, S.-M., Miller, M., Toigo, T., Chen, M., Sahajwalla, C., Lesko, L. J., and Temple, R. 2004. Evaluation of Drugs in Women: Regulatory Perspective - in Section 11, Drug Metabolism/Clinical pharmacology (section editor: Schwartz, J), pp. 848-859, in "Principles of Gender-Specific Medicine," Ed., Legato M, Academic Press.
47. Huang, S.-M., and Lesko, L. J. 2004. Drug-drug, drug-dietary supplement and drug-citrus fruit and other food interactions- what have we learned? J. Clin. Pharmacol. 44:559-569.
48. Huang, S.-M. "Regulatory issues in genotyping metabolizing enzymes- CDER Perspective", presentation at the FDA/PhRMA/JHU educational workshop, September 13-14, 2004, Rockville, MD: http://www.fda.gov/cder/offices/ ocpb/workshops.htm [accessed June 2, 2005].
49. Huang, S.-M., and Lesko, L. J. 2005. Application of Pharmacogenomics in Clinical Pharmacology - in Volume I: Molecular Medicine, Correlation between genes, diseases and biopharmaceuticals, in "Modern Biopharmaceuticals- Design, Development and Optimization", Ed., Jorg Knablein and RH Muller, Wiley, VCH, pages 49-70.
50. Human cytochrome P450 (CYP) nomenclature committee web http://www.imm.ki.se/cypalleles/ [last accessed September 4, 2004].
51. ICH E5 1998. Guidance on Ethnic Factors in the Acceptability of Foreign Clinical Data: http://www.fda.gov/cder/guidance/index.htm, E5 Questions and Answers (2004) http://www.fda.gov/cder/guidance/6200fnl.pdf [accessed September 4, 2004].
52. Innocenti, F., Undevia, S. D., Iyer, L., Chen, P. X., Das, S., Kocherginsky, M., Karrison, T., Janisch, L., Ramirez, J., Rudin, C. M., Vokes, E. E., and Ratain, M. J. 2004. Genetic variants in the UDP- glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. 22:1382-1388. Epub 2004 Mar 08.
53. Israel, E., Drazen, J. M., Liggett, S. B., Boushey, H. A., Cherniack, R. M., Chinchilli, V. M., Cooper, D. M., Fahy, J. V., Fish, J. E., Ford, J. G., Kraft, M., Kunselman, S., Lazarus, S. C., Lemanske, R. F. Jr, Martin, R. J., McLean, D. E., Peters, S. P., Silverman, E. K., Sorkness, C. A., Szefler, S. J., Weiss, S. T., and Yandava, C. N. 2001. National Heart, Lung, and Blood Institute's Asthma Clinical Research Network, Effect of polymorphism of the beta(2)-adrenergic receptor on response to regular use of albuterol in asthma. Int. J. Arch. Allergy Immunol. 124:183-186.
54. Iyer, L., Das, S., Janisch, L., Wen, M., Ramirez, J., Karrison, T., Fleming, G. F., Vokes, E. E., Schilsky, R. L., and Ratain, M. J. 2002. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2:43-47.
55. Kim, R. B., Leake, B. F., Choo, E. F., Dresser, G. K., Kubba, S. V., Schwarz, U. I., Taylor, A., Xie, H. G., McKinsey, J., Zhou, S., Lan, L. B., Schuetz, J. D., Schuetz, E. G., and Wilkinson, G. R. 2001. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 70:189-199.
56. Lazarou, J., Pomeranz, B. H., and Corey, P. N. 1998. Incidence of Adverse Drug Reactions in Hospitalized Patients, A Meta-analysis of Prospective Studies. JAMA 279:1200-1205.
57. Lesko, L. J., Salerno, R. A., Spear, B. B., Anderson, D. C., Anderson, T., Brazell, C., Collins, J., Dorner, A., Essayan, D., Gomez-Mancilla, B., Hackett. J., Huang. S. M., Ide, S., Killinger, J., Leighton, J., Mansfield, E., Meyer, R., Ryan, S. G., Schmith, V., Shaw, P., Sistare, F., Watson, M., Worobec, A. 2003. Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: report of the first FDA-PWG-PhRMA-DruSafe Workshop. J Clin. Pharmacol. 43:342-358.
58. Leighton, J. K., DeGeorge, J., Jacobson-Kram, D., MacGregor, J., Mendrick, D., Worobec, A. 2004. Pharmacogenomic data submissions to the FDA: non-clinical case studies. Pharmacogenomics 5:507-511.
59. Lesko, L. J., and Woodcock, J. 2004. Translation of pharmacogenomics and pharmacogenetics: A regulatory perspective. Nat. Rev. Drug Discov. 3:763-769.
60. Liou, Y. J., Wang, Y. C., Bai, Y. M., Lin, C. C., Yu, S. C., Liao, D. L., Lin, M. W., Chen, J. Y. and Lai, I. C. 2004. Cytochrome P-450 2D6* 10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology 49:167-173.
61. Louis, E., El Ghoul, Z., Vermeire, S., Dall'Ozzo, S., Rutgeerts, P., Paintaud, G., Belaiche, J., De Vos, M., Van Gossum, A., Colombel, J. F., and Watier, H. 2004. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment. Pharmacol. Ther. 19:511-519.
62. Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., Louis, D. N., Christiani, D. C., Settleman, J., and Haber, D. A. 2004. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350:2129-2139. Epub 2004 Apr 29.
63. Milos, P. "Special consideration of individual metabolic biomarkers: CYP2C9" presentation at the FDA/PhRMA/JHU educational workshop, September 13-14, 2004, Rockville, MD: http://www.fda.gov/cder/offices/ocpb/workshops. htm [accessed June 2, 2005].
64. McLeod, H. L., Krynetski, E. Y., Relling, M. V., and Evans, W. E. 2000. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia. 14:567-572.
65. Niemi, M., Leathart, J. B., Neuvonen, M., Backman, J. T., Daly, A. K., and Neuvonen, P. J. 2003. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin. Pharmacol. Ther. 74:380-387.
66. Nishizato, Y., Ieiri, I., Suzuki, H., Kimura, M., Kawabata, K., Hirota, T., Takane, H., Irie, S., Kusuhara, H., Urasaki, Y., Urae, A., Higuchi, S., Otsubo, K., and Sugiyama, Y. 2003. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics. Clin. Pharmacol. Ther. 73:554-565.
67. Otterness, D., Szumlanski, C., Lennard, L., Klemetsdal, B., Aarbakke, J., Park-Hah, J. O., Iven, H., Schmiegelow, K., Branum, E., O'Brien, J., and Weinshilboum, R. 1997. Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms. Clin. Pharmacol. Ther. 62:60-73.
68. Priori, S. G., Napolitano, C., Schwartz, P. J., Grillo, M., Bloise, R., Ronchetti, E., Moncalvo, C., Tulipani, C., Veia, A., Bottelli, G., and Nastoli, J. 2004. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA 292:1341-1344.
69. Phillips, K. A., Veenstra, D. L., Oren, E., Lee, J. K., Sadee, W. 2001. Potential Role of Pharmacogenomics in Reducing Adverse Drug Reactions: A Systematic Review. JAMA 286:2270-2279.
70. Pauli-Magnus, C., and Kroetz, D. L. 2004. Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1). Pharm. Res. 21:904-913.
71. Peyvandi, F., Spreafico, M., Siboni, S. M., Moia, M., and Mannucci, P. M. 2004. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Clin. Pharmacol. Ther. 75:198-203.
72. Ratain, M. "Special consideration of individual metabolic biomarkers: UGT1A1" presentation at the FDA/PhRMA/JHU educational workshop, September 13-14, 2004, Rockville, MD: http://www.fda.gov/cder/offices/ ocpb/workshops.htm
73. Rouits, E., Boisdron-Celle, M., Dumont, A., Guerin, O., Morel, A., and Gamelin, E. 2004. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: A molecular and clinical study of 75 patients. Clin. Cancer Res. 10:5151-5159.
74. Ruaño, G., Collins, J. M., Dorner, A. J., Wang, S.-J., Guerciolini, R., and Huang, S.-M. 2004. Pharmacogenomic data submissions to the FDA: Clinical pharmacology case studies. Pharmacogenomics 5: 513-517.
75. Ruano, G., et al. XIV International Symposium on Drugs Affecting Lipid Metabolism, July 12, 2003: abstract in 52nd Annual American College of Cardiology (Scientific Session) March 30-April 2, 2003, Chicago, IL.
76. Sai, K., Saeki, M., Saito, Y., Ozawa, S., Katori, N., Jinno, H., Hasegawa, R., Kaniwa, N., Sawada, J., Komamura, K., Ueno, K., Kamakura, S., Kitakaze, M., Kitamura, Y., Kamatani, N., Minami, H., Ohtsu, A., Shirao, K., Yoshida, T., and Saijo, N. 2004. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin. Pharmacol. Ther. 75:501-515.
77. Salerno, R. A., and Lesko, L. J. 2004a. Pharmacogenomic data: FDA voluntary and required submission guidance. Pharmacogenomics 5:503-505.
78. Salerno, R. A., and Lesko, L. J. 2004b. Pharmacogenomics in drug development and regulatory decision-making: The Genomic Data Submission (GDS) proposal. Pharmacogenomics 5:25-30.
79. Sai, K., Saeki, M., Saito, Y., Ozawa, S., Katori, N., Jinno, H., Hasegawa, R., Kaniwa, N., Sawada, J., Komamura, K., Ueno, K., Kamakura, S., Kitakaze, M., Kitamura, Y., Kamatani, N., Minami, H., Ohtsu, A., Shirao, K., Yoshida, T., Saijo, N. 2004. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin. Pharmacol. Ther. 75:501-515.
80. Siddiqui, A., Kerb, R., Weale, M. E., Brinkmann, U., Smith, A., Goldstein, D. B., Wood, N. W., and Sisodiya, S. M. 2003. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB. N. Engl. J. Med. 348:1442-1448.
81. Stearns, V., Johnson, M. D., Rae, J. M., Morocho, A., Novielli, A., Bhargava, P., Hayes, D. F., Desta, Z., and Flockhart, D. A. 2003. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl. Cancer Inst. 95:1758-1764.
82. Temple, R. J. 2003. Defining dose decrease. [Comment on Cross, J., Lee, H., Westelinck, A., Nelson, J., Grudzinskas, C., and Peck, C. Postmarketing drug dosage changes of 499 PDA-approved new molecular entities, 1980-1999. Pharmacoepidemiol. Drug Saf. 2002 11:439-16], Pharmacoepidemiol. Drug Saf. 12:151-152.
83. Thorn, C.F., Carrillo, M. W., Ramirez, J., Marsh, S., Schuetz, E. G., Dolan, M. E., Innocenti, F., Relling, M. V., McLeod, H. L., and Ratain, M. J. Irinotecan pathway: http://www.pharmgkb.org/search/pathway/irinotecan/liver.jsp, last updated March 10, 2005.
84. Trepicchio, W. L., Williams, G. A., Essayan, D., Hall, S. T., Harty, L. C., Shaw, P. M., et al. 2004. Pharmacogenomic data submissions to the FDA: Clinical case studies. Pharmacogenomics 5:519-524.
85. Tsuchiya, K., Gatanaga, H., Tachikawa, N., Teruya, K., Kikuchi, Y., Yoshino, M., Kuwahara, T., Shirasaka, T., Kimura, S., and Oka, S. 2004. Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem. Biophys. Res. Commun. Jul 9; 319(4):1322-1326.
86. Wan, Y. J., Poland, R. E., Han, G., Konishi, T., Zheng, Y. P., Berman, N., and Lin, K. M. 2001. Analysis of the C YP2D6 gene polymorphism and enzyme activity in African-Americans in southern California. Pharmacogenetics 11:489-499.
87. Weinshilboum, R. 2003. Inheritance and drug response. N. Engl. J. Med. 348:529-537.
88. Weinshilboum, R. 2001. Thiopurine pharmacogenetics: Clinical and molecular studies of thiopurine methyltransferase. Drug. Metab. Dispos. 29(4 Pt 2): 601-605.
89. Weinshilboum, R., and Wang, L. 2004. Pharmacogenomics: Bench to bedside. Nat. Rev. Drug Discov. 3:739-748.
90. Xie, H. G., Kim, R. B., Wood, A. J., and Stein, C. M. 2001. Molecular basis of ethnic differences in drug disposition and response. Annu. Rev. Pharmacol. Toxicol. 41:815-850.
91. Xu, C., Rao, Y. S., Xu, B., Hoffmann, E., Jones, J., Sellers, E. M., and Tyndale, R. F. 2002. An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. Biochem. Biophys. Res. Commun. 290:318-324.
92. Yang, P., Kanki, H., Drolet, B., Yang, T., Wei, J., Viswanathan, P. C., Hohnloser, S. H., Shimizu, W., Schwartz, P. J., Stanton, M., Murray, K. T., Norris, K., George, A. L. Jr., and Roden, D. M. 2002. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 105:1943-1948.
93. Yasui-Furukori, N., Takahata, T., Nakagami, T., Yoshiya, G., Inoue, Y., Kaneko, S., and Tateishi, T. 2004. Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. Br. J. Clin. Pharmacol. 57:487-494.
94. Yin, O. Q. P., Tomlinson, B., Waye, M. M. Y., Chow, A. H. L., and Chow, M. S. S. Pharmacogenetics and herb-drug interactions: Experience with Ginkgo bilobaand omeprazole. Pharmacogenetics (in press).
95. Zheng, H., Zeevi, A., Schuetz, E., Lamba, J., McCurry, K., Griffith, B. P., Webber, S., Ristich, J., Dauber, J., Iacono, A., Grgurich, W., Zaldonis, D., McDade, K., Zhang, J., and Burckart, G. J. 2004. Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. J. Clin. Pharmacol. 44:135-140.
96. Zheng, H. X., Burckart, G. J., McCurry, K., Webber, S., Ristich, J., Iacono, A., Dauber, J., McDade, K., Grgurich, W., Zaldonis, D., Pillage, G., Griffith, B. P., and Zeevi, A. 2004. Interleukin-10 production genotype protects against acute persistent rejection after lung transplantation. J. Heart Lung Transplant. 23:541-546.